To prepare a regulatory submission for the EMA, you need to compile a Complete Technical Dossier in the Common Technical Document (CTD) format, select the appropriate regulatory pathway, and engage with the EMA early in the process. The submission must cover quality, safety, and efficacy data structured across five CTD modules. The sections below answer the most common questions companies face when preparing an EMA submission.
What documents are required for an EMA regulatory submission?
An EMA regulatory submission requires a complete dossier in the Common Technical Document (CTD) format, organised across five modules. Module 1 contains administrative and regional information, Module 2 provides summaries and overviews, Module 3 covers quality (CMC) data, Module 4 contains non-clinical study reports, and Module 5 includes clinical trial data.
Within these modules, you will need to provide a comprehensive set of documents, including:
- Application form and cover letter
- Product information documents (Summary of Product Characteristics, labelling, and package leaflet)
- Quality documentation covering drug substance and drug product manufacturing
- Non-clinical pharmacology, pharmacokinetics, and toxicology reports
- Clinical pharmacology, efficacy, and safety study reports
- Risk management plan (RMP)
- Environmental risk assessment (where applicable)
For biologics and advanced therapy medicinal products (ATMPs), additional documentation is typically required, including comparability data, viral safety information, and specific manufacturing controls. The completeness and consistency of these documents across all modules is critical. Missing or inconsistent data is one of the most frequent causes of delays during the validation phase.
Which regulatory pathway should you choose for EMA approval?
The right regulatory pathway for EMA approval depends on your product type, the available clinical evidence, and your development timeline. The main options are the centralised procedure, which is mandatory for certain product categories such as biologics and ATMPs, and the decentralised or mutual recognition procedures for products not requiring central authorisation.
Within the centralised procedure, several application types are available:
- Full application (Article 8(3)): Requires a complete quality, non-clinical, and clinical data package.
- Generic application (Article 10(1)): Used when a reference medicinal product has been authorised for at least eight years.
- Hybrid application (Article 10(3)): Combines reference product data with new clinical studies, used when full bioequivalence cannot be established.
- Biosimilar application (Article 10(4)): Requires a comparability exercise against an EMA-approved reference biologic.
- Well-established use application (Article 10a): Relies on published scientific literature instead of original clinical trial data.
Accelerated assessment, conditional marketing authorisation, and exceptional circumstances are additional options for products with unmet medical need or limited data. Choosing the wrong pathway can result in significant delays, so engaging with the EMA through Scientific Advice before submission is strongly recommended. Our team at Starodub can help you evaluate your options — learn more about our regulatory services to see how we support pathway selection from the outset.
How long does the EMA review process take?
The standard EMA review process under the centralised procedure takes 210 active review days, though clock stops can extend the total calendar time to 12 to 15 months or longer. Clock stops occur when the CHMP issues a List of Outstanding Issues and the applicant needs time to prepare responses. The actual elapsed time from submission to approval often exceeds one year.
Accelerated assessment reduces the active review period to 150 days for products of major public health interest. However, accelerated assessment can revert to the standard timeline if the CHMP determines the dossier is more complex than initially assessed.
Preparation time before submission also adds to the overall timeline. Depending on the complexity of the product and the completeness of the data package, pre-submission activities, including scientific advice, pre-submission meetings, and dossier compilation, can take anywhere from several months to several years.
What is the role of the CHMP in EMA submissions?
The Committee for Medicinal Products for Human Use (CHMP) is the EMA scientific committee responsible for evaluating marketing authorisation applications and issuing opinions on whether a medicine should be approved in the EU. Its opinion forms the basis for the European Commission’s final marketing authorisation decision.
During the review process, the CHMP appoints a rapporteur and co-rapporteur from its member states to lead the scientific assessment. These rapporteurs prepare assessment reports, which are reviewed by the full committee. If questions arise, the CHMP issues a List of Outstanding Issues, and the applicant must provide written or oral explanations before the procedure can progress.
The CHMP also plays a role beyond initial authorisation. It evaluates post-authorisation measures, variations to approved products, and referral procedures when safety concerns emerge across the EU. Understanding how the CHMP operates and what it prioritises in its assessments helps applicants structure their dossiers more effectively.
How do you prepare a CMC section for an EMA dossier?
The CMC (Chemistry, Manufacturing, and Controls) section of an EMA dossier, documented in Module 3, must provide a complete and transparent account of the drug substance and drug product, including manufacturing processes, specifications, analytical methods, stability data, and container closure systems. The level of detail required reflects the complexity of the product and the manufacturing process.
Drug substance requirements
For the drug substance, Module 3 must cover the manufacturer’s details, a description of the manufacturing process and process controls, characterisation including elucidation of structure and impurity profile, specifications with justified acceptance criteria, validation of analytical procedures, and stability data supporting the proposed retest period or shelf life.
Drug product requirements
For the drug product, the dossier must include the pharmaceutical development rationale, manufacturing process description and validation, excipient justification, finished product specifications, and stability studies conducted under ICH conditions. For biologics, additional sections on viral safety, comparability, and post-translational modifications are required.
A well-prepared CMC section anticipates the CHMP’s questions by providing clear justifications for all critical quality attributes and control strategies. Gaps in process validation data or insufficient stability data are among the most common triggers for major objections during review. If you would like to understand how Starodub approaches CMC dossier preparation, visit our company page for an overview of our expertise and background.
What are the most common reasons EMA submissions get rejected or delayed?
EMA submissions are most commonly delayed or rejected due to insufficient clinical efficacy data, unresolved safety concerns, incomplete CMC documentation, and failure to address known regulatory requirements for the product category. These issues often reflect gaps in planning rather than fundamental flaws in the product itself.
The most frequently cited causes include:
- Inadequate clinical evidence: Trials that are underpowered, poorly designed, or do not reflect the proposed indication can lead to a negative CHMP opinion.
- Unresolved benefit-risk balance: Safety signals that are not adequately characterised or mitigated through risk minimisation measures raise significant concerns.
- Incomplete or inconsistent CMC data: Missing process validation data, insufficient stability studies, or inconsistencies between modules are common grounds for major objections.
- Failure to follow scientific advice: Applicants who deviate from previously agreed development plans without justification often face additional scrutiny.
- Inadequate risk management plan: An RMP that does not adequately identify and address safety concerns is a frequent source of questions.
Early engagement with the EMA through Scientific Advice and Protocol Assistance significantly reduces the risk of these issues. Addressing potential gaps proactively before submission is far more efficient than responding to major objections during the review clock.
How Starodub supports your EMA regulatory submission
Preparing a successful EMA submission requires both deep regulatory expertise and hands-on experience with the practical demands of dossier compilation. At Starodub, we support biopharmaceutical companies at every stage of the process, from pathway selection and pre-submission planning through to dossier preparation and post-submission query management.
Our services in this area include:
- Regulatory strategy development and pathway assessment for small molecules, biologics, ATMPs, and combination products
- CMC dossier preparation and gap analysis for Module 3
- Coordination of scientific advice and pre-submission meetings with the EMA
- Preparation of responses to CHMP Lists of Outstanding Issues
- Risk management plan development and post-authorisation support
- Full submission project management, including eCTD compilation and submission
With over 400 completed projects and a team of specialists in regulatory affairs, CMC, and quality, we bring the practical knowledge needed to prepare submissions that meet the EMA’s scientific and procedural standards. If you are preparing an EMA submission and want expert support from strategy through approval, contact us today to discuss how we can help.
Related Articles
- How do you achieve GMP compliance for the first time?
- Can small manufacturers realistically maintain full GMP compliance?
- CE Marking for Medical Devices: A Step-by-Step Guide
- ATMP Regulation in Europe: What Developers of Cell and Gene Therapies Need to Know
- What does Class II medical device classification mean?
This content was generated with the help of AI and it may contain mistakes
